South Korea, US Discuss Chip Investments Amid Tariff Plans 
OpenAI Rejects Apple Trade Secret Theft Claims 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
Xiaomi Shares Jump on Europe EV Expansion Plan 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Milei Threatens Falkland Oil Firms With Sanctions 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
OpenAI Nears Astra AI Model Launch With Safety Focus 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Add as a preferred source on Google
BOSTON, March 07, 2018 -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced that company management will present a corporate update at two investor conferences in March:
Cowen and Company 38th Annual Health Care Conference
Date: Wednesday, March 14, 2018
Time: 10:40 a.m. ET
Location: Boston, MA
17th Annual Needham Healthcare Conference
Date: Wednesday, March 28, 2018
Time: 1:30 p.m. ET
Location: New York, NY
Live audio webcasts of both presentations will be available under “Events & Presentations” in the Investors & Media section of the Company’s website at www.rhythmtx.com. Replays of the webcasts will be available on the Rhythm website for 30 days following each presentation.
About Rhythm
Rhythm is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of rare genetic disorders of obesity. Rhythm’s lead product candidate is setmelanotide, a first-in-class melanocortin-4 receptor (MC4R) agonist. Rhythm also supports The Genetic Obesity Project (www.GeneticObesity.com), which is dedicated to improving the understanding of severe obesity that results from specific genetic disorders. The company is based in Boston, MA.
Investor Contact:
Hannah Deresiewicz
Stern Investor Relations, Inc.
212-362-1200
[email protected]
Media Contact:
Adam Daley
Berry & Company Public Relations
212-253-8881
[email protected]
